Please assess the completion status of the following clinical trial:

Trial Title: Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female subjects (40 years of age and older).~* Patients with diagnosis of COPD according to the GOLD guidelines.~* Post-bronchodilator FEV1 \<80% of the predicted value at the screening visit.~* Post-bronchodilator FEV1/FVC ratio ≤0.70 at the screening visit.~* Current or former smokers (e.g., with history of = 10 pack-years).~* Written informed consent.~Exclusion Criteria:~* Known respiratory disorder other than COPD including, but not limited to the following: alpha-1 antitrypsin deficiency, cystic fibrosis, significant asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease.~* History of allergy or hypersensitivity to anticholinergic/muscarinic receptor antagonist agents, beta-2 adrenergic agonists, lactose/milk proteins, or known hypersensitivity to any of the proposed ingredients or components of the delivery system.~* Hospitalization for COPD or pneumonia within 12 weeks prior to the screening visit.~* Treatment for COPD exacerbation within 12 weeks prior to the screening visit.~* Viral or bacterial upper or lower respiratory tract infection, sinusitis, sinus infection, rhinitis, pharyngitis, middle ear infection, urinary tract infection, or illness within 6 weeks prior to the screening visit.~* Abnormal and significant ECG finding prior to the screening, during the run-in and treatment periods.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Product (tiotropium bromide inhalation powder) (Type: EXPERIMENTAL): Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
- Reference Product (Spiriva®) (Type: ACTIVE_COMPARATOR): Single dose of reference product (Spiriva®) 18 mcg
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo inhalation powder

Based on this trial design, predict the completion outcome and termination type (if applicable).